JPM24: ReCode CEO Shehnaaz Suliman eyes second half IPO opportunity
As green shoots slowly push from the scorched Earth biotech markets, ReCode Therapeutics CEO Shehnaaz Suliman, M.D., is watching closely, biding her time for a potential second half IPO. | As green...
fiercebiotech.com